The duo have already collaborated to develop bio-based ingredients from isoflavonoids, using the “” of Biosyntiahighly optimized fermentation platform “However, this is Biosyntia’s first foray into botanical ingredients.
Biosyntia CEO Martin Plambech comments: “This is a very promising new market for us and our technologies. Have
“The global botanical extract market has a business-to-business value of several billion euros and continues to grow rapidly at 9% per year.. ”
Plambech has previously expressed the wish to continuously focus on new collaborations and partnerships with biotechnology companies in order to accelerate the development of new products.
The company recently struck a deal with Givaudan to develop ingredients for food and drink, but this latest collaboration promises to make it easier to produce ‘thousands of high-quality flavonoids that were not possible to produce before ‘, he said.
Under the agreement, Biosyntia will focus on the development and production of affordable active ingredients, leaving Lantana free to focus on generating new high-performance strains.
The first flavonoid in development is fermented kaempferol, which Biosyntia says has a potential market value of € 5 billion (£ 4.2 billion). It is found in certain fruits, vegetables and herbs, and has a range of therapeutic qualities, including as an antioxidant, anti-inflammatory, antimicrobial, antidiabetic and anticancer.
Plambech comments: “HaveWe will target the personal care and nutritional supplement markets, where consumers can use the products in health areas such as anti-aging, vascular health, neuroprotection, cognition and others.Have
Production will take place in Europe at ‘eliminate supply problems’, With a launch planned in the course of “the next two years”.
The fermented variant will represent the first such ingredient commercially available, although the resulting antiviral supplement is initially only available in the United States and others. “selected”regions. Further global expansion will be subject to regulatory approvals.
The two companies will initially rely on existing technology but will also develop proprietary manufacturing processes to optimize the production of new strains from “more”flavonoid variants.
Plambech explains that the vast majority of flavonoids are currently not available for the consumer market, and those that are are generally low-quality and expensive.
“The main reason being that the concentration in plants is so low that it is difficult and expensive to produce them by extraction. Our production technology will allow us to access affordable prices in most consumer applications ”,he said.
Biosyntia’s “technological platform(Biosynthetic Selections) uses a microbial fermentation process to develop vitamins and other active ingredients, in order to significantly reduce its environmental footprint.
It allows millions of modified microorganisms to be detected each week to assess their production efficiency and represents considerable savings per microbe.
The fermentation technique is easily scalable, economical and sustainable, and is based entirely on natural and renewable raw materials.
“It uses sugar (and possibly biological waste) as a raw material which requires (no pesticides or fertilizers) much less arable land than current extraction technologies”,said Plambech.
“Another advantage of the fermentation process is the reduced need for solvents and less waste generated.”Have